C11orf82 Polyklonaler Antikörper

C11orf82 Polyklonal Antikörper für WB, ELISA

Wirt / Isotyp

Kaninchen / IgG

Getestete Reaktivität

human

Anwendung

WB, ELISA

Konjugation

Unkonjugiert

Kat-Nr. : 27754-1-AP

Synonyme

noxin, Nitric oxide-inducible gene protein, DNA damage-induced apoptosis suppressor protein, DNA Damage Induced Apoptosis Suppressor, DDIAS

---

• 

  WB analysis using 27754-1-AP

  Various lysates were subjected to SDS PAGE followed by western blot with 27754-1-AP (C11orf82 antibody) at dilution of 1:1000 incubated at room temperature for 1.5 hours.

---

Geprüfte Anwendungen

• Erfolgreiche Detektion in WB: HepG2-Zellen, K-562-Zellen, NCI-H1299-Zellen

Empfohlene Verdünnung

• Western Blot (WB): WB : 1:500-1:2000

It is recommended that this reagent should be titrated in each testing system to obtain optimal results.

Sample-dependent, check data in validation data gallery

Produktinformation

27754-1-AP bindet in WB, ELISA C11orf82 und zeigt Reaktivität mit human

• Getestete Reaktivität: human
• Wirt / Isotyp: Kaninchen / IgG
• Klonalität: Polyklonal
• Typ: Antikörper
• Immunogen: C11orf82 fusion protein Ag26829
• Vollständiger Name: chromosome 11 open reading frame 82
• Beobachtetes Molekulargewicht: 120 kDa
• GenBank-Zugangsnummer: BC039268
• Gene symbol: C11orf82
• Gene ID (NCBI): 220042
• Konjugation: Unkonjugiert
• Form: Liquid
• Reinigungsmethode: Antigen-Affinitätsreinigung
• Lagerungspuffer: PBS with 0.02% sodium azide and 50% glycerol
• Lagerungsbedingungen: Bei -20°C lagern. Nach dem Versand ein Jahr lang stabil Aliquotieren ist bei -20^oC Lagerung nicht notwendig. 20ul Größen enthalten 0,1% BSA.

Hintergrundinformationen

DNA damage-induced apoptosis suppressor (DDIAS) is an oncogenic protein that is highly expressed in several cancers, including colorectal, lung, breast, and hepatocellular carcinoma (HCC), and stimulates cancer cell proliferation and cell cycle progression.DDIAS protects cancer cells from DNA damage reagents and tumor necrosis factor-associated apoptosis-inducing ligands (TRAILs) and positively regulates cancer cell invasion by stabilizing the β- catenin positively regulates cancer cell invasion. Therefore, DDIAS is considered as a potential therapeutic target for malignant lung cancer.